Antiplatelet Therapy in Patients with Glucose-6-Phosphate Dehydrogenases Deficiency After Percutaneous Coronary Intervention: A Reappraisal for clinical and interventional cardiologists
Glucose-6-phosphate dehydrogenase (G6PD) deficiency represents one of the most common erythrocyte enzymopathy. In the era of drug-eluting stents (DESs), the use of prolonged dual antiplatelet therapy (DAPT) with aspirin (ASA) and thienopyridine (clopidogrel or ticlopidine) has becomes mandatory in the treatment of patients with acute coronary syndromes (ACS) and/or after percutaneous coronary intervention (PCI). However, the use of ASA, and more in general of antiplatelet drugs in patients with G6PD deficiency remains controversial, also for the absence of specific guidelines and scientific evidences.
Source: Cardiovascular Revascularization Medicine - Category: Cardiology Authors: Marco Zuin, Gianluca Rigatelli, Mauro Carraro, Maria Paola Galasso, Fabio Dell'Avvocata, Rossella Paolini, Giovanni Zuliani, Loris Roncon Tags: Mini-review Source Type: research
More News: Angioplasty | Aspirin | Cardiology | Cardiovascular | Clopidogrel | Coronary Angioplasty | G6PD | Heart | Percutaneous Coronary Intervention | Plavix